Last reviewed · How we verify
Rifabutin 150 MG
Rifabutin 150 MG, developed by the University of Bari, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and patent protection, which helps maintain its competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Rifabutin 150 MG |
|---|---|
| Also known as | Mycobutin |
| Sponsor | University of Bari |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) (PHASE2, PHASE3)
- Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels (PHASE1)
- Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains (PHASE4)
- 14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection (PHASE4)
- Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR (PHASE3)
- Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs (PHASE1)
- Effectiveness of Rifabutin for Treatment of Helicobacter Pylori (PHASE3)
- Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifabutin 150 MG CI brief — competitive landscape report
- Rifabutin 150 MG updates RSS · CI watch RSS
- University of Bari portfolio CI